A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.

Although there was a trend toward inferior outcome in patient with elevated LDH, this did not reach statistical significance (p=0.53), perhaps due to the limited number of patients who presented with an elevated LDH in our clinical practice.

also in 111,027 other papers